Caat55 wrote:Any news on a vaccine, heard it mentioned on NPR on Monday?
As consumption of sugar-laden drinks rose in the 1980s and ’90s, so did colorectal cancer rates among younger adults, a study in nurses found.
Colon and rectal cancers are rising in younger adults, though researchers aren’t sure why. A new study of women and diet suggests that sugar-sweetened drinks may play a role.
Rates of colorectal cancer in people under 50 have increased sharply in recent years. Compared with people born around 1950, those born around 1990 have twice the risk for colon cancer and four times the risk for rectal cancer.
With the increasingly prominent role of targeted therapy in the treatment of advanced or mCRC disease, the NCCN expert group has expanded its recommendations on biomarker testing.
At present, for patients with mCRC, it is recommended to determine the tumor gene status of KRAS/NRAS and BRAF mutations, as well as HER2 amplification and MSI/MMR status (if not completed in the past). Although no specific method is recommended, it can be tested on individual genes or as part of an NGS group.
An overview of what is currently understood about the use of ctDNA assays to help guide treatment decisions when managing patients with colorectal cancer undergoing resection of metastases.
Associations of BMI at Different Ages With Early-Onset Colorectal Cancer
Obesity, particularly in early adulthood, increases the risk of early-onset colorectal cancer, which highlights the need for personalized screening strategies.
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab for Metastatic Colorectal Cancer
Additional prospective studies can help validate the use of upfront intensive chemotherapy to increase tumour immunogenicity and enhance the antitumour effect of atezolizumab in patients with metastatic colorectal cancer.
Postoperative ctDNA Combined With Consensus Molecular Subtypes to Improve Risk Stratification in Stage III Colon Cancers
Incorporating the use of ctDNA and CMS in stage III colon cancer risk stratification adds prognostic value. Future studies are necessary to validate their clinical utility and role in individualizing postoperative chemotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
This phase II trial of dostarlimab in patients with mismatch repair (MMR)–deficient locally advanced rectal cancer showed that the use of PD-1–directed therapy with dostarlimab in the neoadjuvant setting was associated with a 100% clinical complete response rate.
Users browsing this forum: Google Feedfetcher and 5 guests